Literature DB >> 7049455

Impairment of T lymphocyte functions in mice with motor end-plate disease.

M Papiernik, F Rieger, S Ezine, M Pincon-Raymond.   

Abstract

The present paper reports complex immunological anomalies associated with motor end-plate disease (Med) in mice. Motor end-plate disease is a severe neuromuscular disorder which leads to death (around the 25th of life) in the Medj/Medj mutant, while the heterozygotes quickly recover from mild manifestations. Medj/Medj and Medj/ + mice share some of the immunological aberrations: reduced PFC response to SRBC in 14-16 day old mice, with reduced suppressor cell function and precocious maturation of the cytotoxic response to allogeneic cells in 21-23 day old mice. The diminished PFC response is corrected in adult Medj/ + mice but persists in the small group of Medj/Medj which escape death and which were studied between the 6th and 16th week of life. In addition, the thymus and spleen of Medj/Medj mice are greatly reduced in size, a symptom which appears with the onset of the clinical disease. Also, a reduction in the NK activity in the small group of older, surviving mice was noted. T and B lymphocyte proportions and the proliferative responses to T cell mitogens were not impaired in 14-16 day old mice. The role of these abnormalities in the pathogenesis of the disease is not known. Since some of these anomalies are shared by Medj/Medj and Medj/ +, the latter of which present no or mild and transient neurological manifestations, there is no clear link between the immunological and neuromuscular disorders.

Entities:  

Mesh:

Year:  1982        PMID: 7049455      PMCID: PMC1536477     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  11 in total

1.  Evidence of a thymic abnormality in murine muscular dystrophy.

Authors:  T A de Kretser; B G Livett
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

2.  Abnormalities of thymus growth in dystrophic mice.

Authors:  R A Karmali; D F Horrobin
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

3.  Induction of antibody-forming cell clones in microcultures.

Authors:  I Lefkovits
Journal:  Eur J Immunol       Date:  1972-08       Impact factor: 5.532

4.  Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.

Authors:  D M Fambrough; D B Drachman; S Satyamurti
Journal:  Science       Date:  1973-10-19       Impact factor: 47.728

5.  Further improvements in the plaque technique for detecting single antibody-forming cells.

Authors:  A J Cunningham; A Szenberg
Journal:  Immunology       Date:  1968-04       Impact factor: 7.397

6.  Immunologic function and cell surface antigen expression of lymphocytes of dystrophic mice.

Authors:  C L Ludwig; C Kanellopoulos-Langevin; K J Kim; B J Mathieson; H C Morse
Journal:  Cell Immunol       Date:  1981-03-15       Impact factor: 4.868

7.  Electrophysiological studies of neuromuscular transmission in hereditary 'motor end-plate disease' of the mouse.

Authors:  L W Duchen; E Stefani
Journal:  J Physiol       Date:  1971-01       Impact factor: 5.182

8.  Deficit of suppressor T cells in active multiple sclerosis.

Authors:  M A Bach; F Phan-Dinh-Tuy; E Tournier; L Chatenoud; J F Bach; C Martin; J D Degos
Journal:  Lancet       Date:  1980-12-06       Impact factor: 79.321

9.  Changes in suppressor mechanisms during postnatal development in mice.

Authors:  C E Calkins; O Stutman
Journal:  J Exp Med       Date:  1978-01-01       Impact factor: 14.307

10.  Cell-mediated immunity: differential maturation of mixed leukocyte reaction and cell-mediated lympholysis.

Authors:  S Wu; F H Bach; R Auerbach
Journal:  J Exp Med       Date:  1975-11-01       Impact factor: 14.307

View more
  1 in total

1.  Modification of helper and suppressor/cytotoxic lymphocyte subsets in mice with motor end-plate disease.

Authors:  S Ezine; M Papiernik; F Rieger; M Pinçon-Raymond
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.